Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Canadian guideline for Parkinson disease.

Grimes D, Fitzpatrick M, Gordon J, Miyasaki J, Fon EA, Schlossmacher M, Suchowersky O, Rajput A, Lafontaine AL, Mestre T, Appel-Cresswell S, Kalia SK, Schoffer K, Zurowski M, Postuma RB, Udow S, Fox S, Barbeau P, Hutton B.

CMAJ. 2019 Sep 9;191(36):E989-E1004. doi: 10.1503/cmaj.181504. No abstract available.

PMID:
31501181
2.

Ripk3 licenced protection against microbial infection in the absence of Caspase1-11 inflammasome.

Shutinoski B, Patel R, Tomlinson JJ, Schlossmacher MG, Sad S.

Microbes Infect. 2019 Aug 17. pii: S1286-4579(19)30085-1. doi: 10.1016/j.micinf.2019.08.002. [Epub ahead of print]

PMID:
31430539
3.

DMS as an orthogonal separation to LC/ESI/MS/MS for quantifying isomeric cerebrosides in plasma and cerebrospinal fluid.

Xu H, Boucher FR, Nguyen TT, Taylor GP, Tomlinson JJ, Ortega RA, Simons B, Schlossmacher MG, Saunders-Pullman R, Shaw W, Bennett SAL.

J Lipid Res. 2019 Jan;60(1):200-211. doi: 10.1194/jlr.D089797. Epub 2018 Nov 9.

PMID:
30413651
4.

Regulation of myeloid cell phagocytosis by LRRK2 via WAVE2 complex stabilization is altered in Parkinson's disease.

Kim KS, Marcogliese PC, Yang J, Callaghan SM, Resende V, Abdel-Messih E, Marras C, Visanji NP, Huang J, Schlossmacher MG, Trinkle-Mulcahy L, Slack RS, Lang AE; Canadian Lrrk2 in Inflammation Team (CLINT), Park DS.

Proc Natl Acad Sci U S A. 2018 May 29;115(22):E5164-E5173. doi: 10.1073/pnas.1718946115. Epub 2018 May 14.

5.

Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting.

Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J.

Neurology. 2018 Jan 9;90(2):74-82. doi: 10.1212/WNL.0000000000004798. Epub 2017 Dec 13.

6.

Candidate inflammatory biomarkers display unique relationships with alpha-synuclein and correlate with measures of disease severity in subjects with Parkinson's disease.

Eidson LN, Kannarkat GT, Barnum CJ, Chang J, Chung J, Caspell-Garcia C, Taylor P, Mollenhauer B, Schlossmacher MG, Ereshefsky L, Yen M, Kopil C, Frasier M, Marek K, Hertzberg VS, Tansey MG.

J Neuroinflammation. 2017 Aug 18;14(1):164. doi: 10.1186/s12974-017-0935-1.

7.

Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects.

Tomlinson JJ, Shutinoski B, Dong L, Meng F, Elleithy D, Lengacher NA, Nguyen AP, Cron GO, Jiang Q, Roberson ED, Nussbaum RL, Majbour NK, El-Agnaf OM, Bennett SA, Lagace DC, Woulfe JM, Sad S, Brown EG, Schlossmacher MG.

J Neural Transm (Vienna). 2017 Jun;124(6):721-738. doi: 10.1007/s00702-017-1726-7. Epub 2017 May 5.

8.

Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the PR EDIGT score.

Schlossmacher MG, Tomlinson JJ, Santos G, Shutinoski B, Brown EG, Manuel D, Mestre T.

Eur J Neurosci. 2017 Jan;45(1):175-191. doi: 10.1111/ejn.13476. Epub 2016 Dec 27.

9.

K45A mutation of RIPK1 results in poor necroptosis and cytokine signaling in macrophages, which impacts inflammatory responses in vivo.

Shutinoski B, Alturki NA, Rijal D, Bertin J, Gough PJ, Schlossmacher MG, Sad S.

Cell Death Differ. 2016 Oct;23(10):1628-37. doi: 10.1038/cdd.2016.51. Epub 2016 Jun 3.

10.

A First Tetraplex Assay for the Simultaneous Quantification of Total α-Synuclein, Tau, β-Amyloid42 and DJ-1 in Human Cerebrospinal Fluid.

Kruse N, Schlossmacher MG, Schulz-Schaeffer WJ, Vanmechelen E, Vanderstichele H, El-Agnaf OM, Mollenhauer B.

PLoS One. 2016 Apr 26;11(4):e0153564. doi: 10.1371/journal.pone.0153564. eCollection 2016.

11.

Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders.

Mollenhauer B, Parnetti L, Rektorova I, Kramberger MG, Pikkarainen M, Schulz-Schaeffer WJ, Aarsland D, Svenningsson P, Farotti L, Verbeek MM, Schlossmacher MG.

J Neurochem. 2016 Oct;139 Suppl 1:290-317. doi: 10.1111/jnc.13390. Epub 2016 Feb 10. Review.

12.

LRRK2 and Nod2 promote lysozyme sorting in Paneth cells.

Rocha JD, Schlossmacher MG, Philpott DJ.

Nat Immunol. 2015 Sep;16(9):898-900. doi: 10.1038/ni.3255. No abstract available.

PMID:
26287588
13.

Protective effect of vagotomy suggests source organ for Parkinson disease.

Gray MT, Munoz DG, Schlossmacher MG, Gray DA, Woulfe JM.

Ann Neurol. 2015 Nov;78(5):834-5. doi: 10.1002/ana.24501. Epub 2015 Sep 22. No abstract available.

PMID:
26267415
14.

Association between α-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease.

Locascio JJ, Eberly S, Liao Z, Liu G, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Dhima K, Hung AY, Flaherty AW, Schwarzschild MA, Hayes MT, Wills AM, Shivraj Sohur U, Mejia NI, Selkoe DJ, Oakes D, Shoulson I, Dong X, Marek K, Zheng B, Ivinson A, Hyman BT, Growdon JH, Sudarsky LR, Schlossmacher MG, Ravina B, Scherzer CR.

Brain. 2015 Sep;138(Pt 9):2659-71. doi: 10.1093/brain/awv202. Epub 2015 Jul 28.

15.

Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative.

Laurens B, Constantinescu R, Freeman R, Gerhard A, Jellinger K, Jeromin A, Krismer F, Mollenhauer B, Schlossmacher MG, Shaw LM, Verbeek MM, Wenning GK, Winge K, Zhang J, Meissner WG.

Neurobiol Dis. 2015 Aug;80:29-41. doi: 10.1016/j.nbd.2015.05.004. Epub 2015 May 15. Review.

PMID:
25982836
16.

Towards translational therapies for multiple system atrophy.

Kuzdas-Wood D, Stefanova N, Jellinger KA, Seppi K, Schlossmacher MG, Poewe W, Wenning GK.

Prog Neurobiol. 2014 Jul;118:19-35. doi: 10.1016/j.pneurobio.2014.02.007. Epub 2014 Mar 2. Review.

17.

Alpha-synuclein in the appendiceal mucosa of neurologically intact subjects.

Gray MT, Munoz DG, Gray DA, Schlossmacher MG, Woulfe JM.

Mov Disord. 2014 Jul;29(8):991-8. doi: 10.1002/mds.25779. Epub 2013 Dec 18.

PMID:
24352892
18.

Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study.

Ding H, Dhima K, Lockhart KC, Locascio JJ, Hoesing AN, Duong K, Trisini-Lipsanopoulos A, Hayes MT, Sohur US, Wills AM, Mollenhauer B, Flaherty AW, Hung AY, Mejia N, Khurana V, Gomperts SN, Selkoe DJ, Schwarzschild MA, Schlossmacher MG, Hyman BT, Sudarsky LR, Growdon JH, Scherzer CR.

Neurology. 2013 Oct 22;81(17):1531-7. doi: 10.1212/WNL.0b013e3182a95818. Epub 2013 Sep 25.

19.

Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort.

Mollenhauer B, Trautmann E, Sixel-Döring F, Wicke T, Ebentheuer J, Schaumburg M, Lang E, Focke NK, Kumar KR, Lohmann K, Klein C, Schlossmacher MG, Kohnen R, Friede T, Trenkwalder C; DeNoPa Study Group.

Neurology. 2013 Oct 1;81(14):1226-34. doi: 10.1212/WNL.0b013e3182a6cbd5. Epub 2013 Aug 30.

PMID:
23997153
20.

Parkin-dependent degradation of the F-box protein Fbw7β promotes neuronal survival in response to oxidative stress by stabilizing Mcl-1.

Ekholm-Reed S, Goldberg MS, Schlossmacher MG, Reed SI.

Mol Cell Biol. 2013 Sep;33(18):3627-43. doi: 10.1128/MCB.00535-13. Epub 2013 Jul 15.

21.

Respiratory infection of mice with mammalian reoviruses causes systemic infection with age and strain dependent pneumonia and encephalitis.

Gauvin L, Bennett S, Liu H, Hakimi M, Schlossmacher M, Majithia J, Brown EG.

Virol J. 2013 Mar 1;10:67. doi: 10.1186/1743-422X-10-67.

22.

Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects.

Mollenhauer B, Trautmann E, Taylor P, Manninger P, Sixel-Döring F, Ebentheuer J, Trenkwalder C, Schlossmacher MG.

Neurosci Lett. 2013 Jan 4;532:44-8. doi: 10.1016/j.neulet.2012.11.004. Epub 2012 Nov 10.

PMID:
23149132
23.

Progressive dopaminergic cell loss with unilateral-to-bilateral progression in a genetic model of Parkinson disease.

Rousseaux MW, Marcogliese PC, Qu D, Hewitt SJ, Seang S, Kim RH, Slack RS, Schlossmacher MG, Lagace DC, Mak TW, Park DS.

Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):15918-23. Epub 2012 Sep 10. Erratum in: Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11212.

24.

Novel one-step immunoassays to quantify α-synuclein: applications for biomarker development and high-throughput screening.

Bidinosti M, Shimshek DR, Mollenhauer B, Marcellin D, Schweizer T, Lotz GP, Schlossmacher MG, Weiss A.

J Biol Chem. 2012 Sep 28;287(40):33691-705. Epub 2012 Jul 27.

25.

Considerations regarding the etiology and future treatment of autosomal recessive versus idiopathic Parkinson disease.

Kitada T, Tomlinson JJ, Ao HS, Grimes DA, Schlossmacher MG.

Curr Treat Options Neurol. 2012 Jun;14(3):230-40. doi: 10.1007/s11940-012-0175-8.

PMID:
22547255
26.

Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid.

Kruse N, Schulz-Schaeffer WJ, Schlossmacher MG, Mollenhauer B.

Methods. 2012 Apr;56(4):514-8. doi: 10.1016/j.ymeth.2012.03.016. Epub 2012 Mar 23. Review.

PMID:
22465793
27.

α-Synuclein in human cerebrospinal fluid is principally derived from neurons of the central nervous system.

Mollenhauer B, Trautmann E, Otte B, Ng J, Spreer A, Lange P, Sixel-Döring F, Hakimi M, Vonsattel JP, Nussbaum R, Trenkwalder C, Schlossmacher MG.

J Neural Transm (Vienna). 2012 Jul;119(7):739-46. doi: 10.1007/s00702-012-0784-0. Epub 2012 Mar 18.

28.

Mutant GBA1 expression and synucleinopathy risk: first insights from cellular and mouse models.

Sardi SP, Singh P, Cheng SH, Shihabuddin LS, Schlossmacher MG.

Neurodegener Dis. 2012;10(1-4):195-202. doi: 10.1159/000335038. Epub 2012 Feb 9. Review.

PMID:
22327140
29.

Association of SNCA with Parkinson: replication in the Harvard NeuroDiscovery Center Biomarker Study.

Ding H, Sarokhan AK, Roderick SS, Bakshi R, Maher NE, Ashourian P, Kan CG, Chang S, Santarlasci A, Swords KE, Ravina BM, Hayes MT, Sohur US, Wills AM, Flaherty AW, Unni VK, Hung AY, Selkoe DJ, Schwarzschild MA, Schlossmacher MG, Sudarsky LR, Growdon JH, Ivinson AJ, Hyman BT, Scherzer CR.

Mov Disord. 2011 Oct;26(12):2283-6. doi: 10.1002/mds.23934. Epub 2011 Sep 23.

30.

CNS expression of glucocerebrosidase corrects alpha-synuclein pathology and memory in a mouse model of Gaucher-related synucleinopathy.

Sardi SP, Clarke J, Kinnecom C, Tamsett TJ, Li L, Stanek LM, Passini MA, Grabowski GA, Schlossmacher MG, Sidman RL, Cheng SH, Shihabuddin LS.

Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):12101-6. doi: 10.1073/pnas.1108197108. Epub 2011 Jul 5.

31.

Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures.

Hakimi M, Selvanantham T, Swinton E, Padmore RF, Tong Y, Kabbach G, Venderova K, Girardin SE, Bulman DE, Scherzer CR, LaVoie MJ, Gris D, Park DS, Angel JB, Shen J, Philpott DJ, Schlossmacher MG.

J Neural Transm (Vienna). 2011 May;118(5):795-808. doi: 10.1007/s00702-011-0653-2. Epub 2011 May 7.

32.

Acid β-glucosidase mutants linked to Gaucher disease, Parkinson disease, and Lewy body dementia alter α-synuclein processing.

Cullen V, Sardi SP, Ng J, Xu YH, Sun Y, Tomlinson JJ, Kolodziej P, Kahn I, Saftig P, Woulfe J, Rochet JC, Glicksman MA, Cheng SH, Grabowski GA, Shihabuddin LS, Schlossmacher MG.

Ann Neurol. 2011 Jun;69(6):940-53. doi: 10.1002/ana.22400. Epub 2011 Apr 6.

PMID:
21472771
33.

Translational research in neurology and neuroscience 2011: movement disorders.

Klein C, Krainc D, Schlossmacher MG, Lang AE.

Arch Neurol. 2011 Jun;68(6):709-16. doi: 10.1001/archneurol.2011.11. Epub 2011 Feb 14. Review.

PMID:
21320985
34.

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.

Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG.

Lancet Neurol. 2011 Mar;10(3):230-40. doi: 10.1016/S1474-4422(11)70014-X. Erratum in: Lancet Neurol. 2011 Apr;10(4):297.

PMID:
21317042
35.

Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies.

Mollenhauer B, El-Agnaf OM, Marcus K, Trenkwalder C, Schlossmacher MG.

Biomark Med. 2010 Oct;4(5):683-99. doi: 10.2217/bmm.10.90. Review.

PMID:
20945981
36.

Biomarker research in Parkinson's disease: objective measures needed for patient stratification in future cause-directed trials.

Schlossmacher MG, Mollenhauer B.

Biomark Med. 2010 Oct;4(5):647-50. doi: 10.2217/bmm.10.93. No abstract available.

37.

CSF synuclein: adding to the biomarker footprint of dementia with Lewy bodies.

Mollenhauer B, Schlossmacher MG.

J Neurol Neurosurg Psychiatry. 2010 Jun;81(6):590-1. doi: 10.1136/jnnp.2010.206391. No abstract available.

PMID:
20522867
38.

Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain.

Cronin KD, Ge D, Manninger P, Linnertz C, Rossoshek A, Orrison BM, Bernard DJ, El-Agnaf OM, Schlossmacher MG, Nussbaum RL, Chiba-Falek O.

Hum Mol Genet. 2009 Sep 1;18(17):3274-85. doi: 10.1093/hmg/ddp265. Epub 2009 Jun 4.

39.

Increased DJ-1 expression under oxidative stress and in Alzheimer's disease brains.

Baulac S, Lu H, Strahle J, Yang T, Goldberg MS, Shen J, Schlossmacher MG, Lemere CA, Lu Q, Xia W.

Mol Neurodegener. 2009 Feb 25;4:12. doi: 10.1186/1750-1326-4-12.

40.

Cathepsin D expression level affects alpha-synuclein processing, aggregation, and toxicity in vivo.

Cullen V, Lindfors M, Ng J, Paetau A, Swinton E, Kolodziej P, Boston H, Saftig P, Woulfe J, Feany MB, Myllykangas L, Schlossmacher MG, Tyynelä J.

Mol Brain. 2009 Feb 9;2:5. doi: 10.1186/1756-6606-2-5.

41.

Vertebral artery dissection with a normal-appearing lumen at multisection CT angiography: the importance of identifying wall hematoma.

Lum C, Chakraborty S, Schlossmacher M, Santos M, Mohan R, Sinclair J, Sharma M.

AJNR Am J Neuroradiol. 2009 Apr;30(4):787-92. doi: 10.3174/ajnr.A1455. Epub 2009 Jan 22.

42.

Multiple system atrophy: a primary oligodendrogliopathy.

Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG.

Ann Neurol. 2008 Sep;64(3):239-46. doi: 10.1002/ana.21465. Review.

PMID:
18825660
43.

GATA transcription factors directly regulate the Parkinson's disease-linked gene alpha-synuclein.

Scherzer CR, Grass JA, Liao Z, Pepivani I, Zheng B, Eklund AC, Ney PA, Ng J, McGoldrick M, Mollenhauer B, Bresnick EH, Schlossmacher MG.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10907-12. doi: 10.1073/pnas.0802437105. Epub 2008 Jul 31.

44.

Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration.

Mollenhauer B, Cullen V, Kahn I, Krastins B, Outeiro TF, Pepivani I, Ng J, Schulz-Schaeffer W, Kretzschmar HA, McLean PJ, Trenkwalder C, Sarracino DA, Vonsattel JP, Locascio JJ, El-Agnaf OM, Schlossmacher MG.

Exp Neurol. 2008 Oct;213(2):315-25. doi: 10.1016/j.expneurol.2008.06.004. Epub 2008 Jun 14.

PMID:
18625222
45.

The effects of oxidative stress on parkin and other E3 ligases.

LaVoie MJ, Cortese GP, Ostaszewski BL, Schlossmacher MG.

J Neurochem. 2007 Dec;103(6):2354-68. Epub 2007 Sep 19.

46.

Parkinson disease, 10 years after its genetic revolution: multiple clues to a complex disorder.

Klein C, Schlossmacher MG.

Neurology. 2007 Nov 27;69(22):2093-104. Epub 2007 Aug 29. Review.

PMID:
17761553
47.

Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.

Mollenhauer B, Steinacker P, Bahn E, Bibl M, Brechlin P, Schlossmacher MG, Locascio JJ, Wiltfang J, Kretzschmar HA, Poser S, Trenkwalder C, Otto M.

Neurodegener Dis. 2007;4(5):366-75. Epub 2007 Jul 6.

PMID:
17622779
48.

Deciphering the role of heterozygous mutations in genes associated with parkinsonism.

Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE.

Lancet Neurol. 2007 Jul;6(7):652-62. Review.

PMID:
17582365
49.

Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo.

Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, Feany MB.

J Neurosci. 2007 Mar 21;27(12):3338-46.

50.

Molecular markers of early Parkinson's disease based on gene expression in blood.

Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, Schwarzschild MA, Schlossmacher MG, Hauser MA, Vance JM, Sudarsky LR, Standaert DG, Growdon JH, Jensen RV, Gullans SR.

Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):955-60. Epub 2007 Jan 10.

Supplemental Content

Loading ...
Support Center